UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000054058 |
|---|---|
| Receipt number | R000061717 |
| Scientific Title | Verification of the effects of test food on cognitive function : Placebo-controlled, double-blind, randomized, two-phase, cross-over comparison study |
| Date of disclosure of the study information | 2024/04/07 |
| Last modified on | 2024/04/03 19:05:00 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Verification of the effects of test food on cognitive function
Acronym
Verification of the effects of test food on cognitive function
Scientific Title
Verification of the effects of test food on cognitive function
: Placebo-controlled, double-blind, randomized, two-phase, cross-over comparison study
Scientific Title:Acronym
Verification of the effects of test food on cognitive function
: Placebo-controlled, double-blind, randomized, two-phase, cross-over comparison study
Region
| Japan |
Condition
Condition
Healthy adults
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To confirm the effect on cognitive function when healthy adult men and women ingest test foods
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Cognitive test
Memory test
Key secondary outcomes
Plasma amyloid beta 1-40
Plasma amyloid beta 1-42
Plasma amyloid beta 1-42/1-40 ratio
glycoalbumin
1, 5-anhydro-D-glucitol
Urinary 8-OHdG
Subjective Indicator Survey
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Ingestion the test food for 24 weeks
Interventions/Control_2
Ingestion the placebo food for 24 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 50 | years-old | <= |
Age-upper limit
| 79 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
(1) Subjects of men and women aged 50 to 79
(2) Subjects who are aware of memory loss
(3) Subjects with a MoCA-J score of 26 or higher
(4) Subjects who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing.
Key exclusion criteria
(1) Subjects with Alzheimer's disease
(2) Subjects with a history of stroke, subarachnoid hemorrhage, cerebral infarction, cerebral hemorrhage, cerebral contusion, or head injury
(3) Subjects with a history of diabetes, liver diseases, renal disease, gastrointestinal disease, cardiac disease, respiratory disease, peripheral vascular disease, or other serious disease.
(4) Subjects who have undergone gastrointestinal surgery
(5) Subjects with abnormal liver and renal function test value
(6) Subjects with diseases currently being treated
(7) Subjects who are allergic to food and drugs
(8) Subjects with anemia symptoms
(9) Subjects with color discrimination difficulties
(10) Subjects who have difficulty performing cognitive function tests due to low visual acuity, or who have been diagnosed with low vision or blindness
(11) Subjects who have depression or have been diagnosed with depression
(12) Subjects with motor, visual or hearing impairments
(13) Subjects who play intense sports and subjects who are on a diet
(14) Subjects who work at night or have other irregularities in their daily life during the examination period
(15) Subjects who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the test period
(16) Subjects who are continuously treated with pharmaceuticals (including OTC and prescription drugs)
(17) Subjects who drink more than 20 g of average daily pure alcohol
(18) Subjects who are participating in or will participate in other clinical trials at the start of this study.
(19) Other subjects judged by the investigator or the investigator to be inappropriate for the examination
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | Naoki |
| Middle name | |
| Last name | Miura |
Organization
Miura Clinic, Medical Corporation Kanonkai
Division name
Internal medicine
Zip code
5300044
Address
Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka
TEL
06-6135-5200
info@miura-cl.jp
Public contact
Name of contact person
| 1st name | Makoto |
| Middle name | |
| Last name | Terashima |
Organization
Oneness Support Co., Ltd.
Division name
Clinical Trial Division
Zip code
5300044
Address
Higashitenma building 4F, 1-7-17, Higashitenma, Kita-ku, Osaka
TEL
06-4801-8917
Homepage URL
mterashima@oneness-sup.co.jp
Sponsor or person
Institute
Miura Clinic, Medical Corporation Kanonkai
Institute
Department
Personal name
Funding Source
Organization
TOWA PHARMACEUTICAL CO.,LTD
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The Ethics Committee of Miura Clinic, Medical Corporation Kanonkai
Address
Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka
Tel
06-6135-5200
mterashima@miura-cl.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人花音会みうらクリニック（大阪府）
Other administrative information
Date of disclosure of the study information
| 2024 | Year | 04 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2024 | Year | 03 | Month | 28 | Day |
Date of IRB
| 2024 | Year | 03 | Month | 28 | Day |
Anticipated trial start date
| 2024 | Year | 05 | Month | 27 | Day |
Last follow-up date
| 2025 | Year | 08 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2024 | Year | 04 | Month | 04 | Day |
Last modified on
| 2024 | Year | 04 | Month | 03 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061717
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
